– Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma – – Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease Patients – – Conference call and live webcast at 8:00 a.m. ET today – DURHAM, N.C., May […]
Other News
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results
— New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit — — First patient dosed in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty in Japan — — Conference call scheduled for 8:30 a.m. ET today — MIAMI, May […]
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
Completed business combination and listing on Nasdaq generating gross proceeds of approximately $70 million BackBeat CNT™ global pivotal study in hypertensive pacemaker patients on track for initiation in the second half of 2023 in collaboration with Medtronic Virtue SAB® U.S. pivotal study in coronary in-stent restenosis (“ISR”) start planned for […]
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint China National Medical Products Administration (NMPA) accepted mavacamten New Drug Application (NDA) with priority review Mavacamten commercial launch preparations continue in China, supported by the promotion of Pascal Qian to Chief Commercial Official Cash, cash equivalents […]
HeartBeam Reports First Quarter 2023 Financial Results
Closed $26.5 Million with a Public Offering and Registered Direct Offering to Enable Company to Execute on Upcoming Clinical, Regulatory and Commercial Milestones and Extend Cash Runway into Late 2024 Strategic Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform Management to Host Webcast […]
Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced financial results for the first quarter ended March 31, 2023. Business Updates Announced the appointment of Gansevoort “Gan” Dunnington, MD, as Chief […]
ConcertAI’s TeraRecon Advances Cardiovascular Visualization with the Launch of Intuition 4.7
State-of-the-art structural heart capabilities simplify pre-op planning for interventional clinicians through automated workflows and enhanced interoperability CAMBRIDGE, Mass., May 11, 2023 /PRNewswire/ — ConcertAI’s TeraRecon, the advanced visualization (AV) and clinical AI SaaS category leader, today announced the global launch of its flagship, best-in-KLAS advanced visualization product, Intuition 4.7. A dedicated structural heart […]
Merck Manuals Breaks Down Differences Between Heart Attack and Cardiac Arrest
Doctor outlines key distinctions and how to respond to both conditions RAHWAY, N.J., May 10, 2023 /PRNewswire/ — The terms “heart attack” and “cardiac arrest” are often used interchangeably. In reality, they are distinct, typically with different causes and requiring different responses in the moment to get the person the help they […]
PFIZER CALLS FOR MORE AWARENESS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) – A RARE, LIFE-THREATENING DISEASE
KUALA LUMPUR, Malaysia, May 11, 2023 /PRNewswire/ — In an effort to encourage people to take care of their heart health, Pfizer Malaysia is calling for Malaysians to learn more about transthyretin amyloid cardiomyopathy (ATTR-CM), a rare, life-threatening disease. ATTR-CM is caused by unstable transthyretin proteins that misfold and aggregate into amyloid […]
CARMAT Announces the Approval of All Resolutions Supported by the Board of Directors at Its Annual General Meeting
The company confirms its sales target of €10-13 million for 2023 PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, informs its shareholders that the Combined General […]
Recent
Efemoral Medical Reports Exceptional Long-Term EFEMORAL I Results Highlighting Durability and Differentiated Performance in Femoropopliteal Disease
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
First Peer-Reviewed Study to Evaluate AI-Generated Impressions Demonstrates Radiologist Preference for Domain-Specific Versus General Models
Popular
- No commented posts yet